Entero Therapeutics Narrows Losses, Boosts Cash Amid Grid AI Acquisition

TL;DR

**GRDX is burning less cash and trying to pivot with Grid AI, but they're still deep in the red and need more capital to survive.**

AI Summary

Entero Therapeutics, Inc. (GRDX) reported a net loss of $3,410,700 for the nine months ended September 30, 2025, a significant improvement from the $5,821,067 net loss in the prior-year period. This 41.4% reduction in net loss was primarily driven by a substantial decrease in general and administrative expenses, which fell from $13,535,241 in 2024 to $2,362,957 in 2025. Research and development expenses also saw a sharp decline, from $882,522 to $32,080. The company's cash and cash equivalents increased dramatically to $2,517,218 as of September 30, 2025, up from $163,476 at December 31, 2024, largely due to $3,025,000 in proceeds from common stock, prefunded warrants, and warrants. A key business change was the acquisition of Grid AI Corp. on September 30, 2025, which introduced $18,387,000 in developed technology and $25,796,163 in goodwill to the balance sheet. The company also reported assets of a disposal group held-for-sale totaling $83,170,009, indicating a strategic divestiture. Despite the improved net loss, the company continues to operate at a loss and faces risks related to maintaining Nasdaq listing requirements and securing additional capital.

Why It Matters

This 10-Q reveals Entero Therapeutics is actively restructuring, evidenced by the Grid AI acquisition and the IMGX subsidiary held-for-sale. For investors, the significant reduction in net loss and increased cash position are positive signs, but the company remains unprofitable and relies on capital raises. Employees at Grid AI are now integrated into a company with a challenging financial history, while IMGX employees face uncertainty. Customers of both entities might see shifts in product focus or service delivery. Competitively, the Grid AI acquisition could signal a pivot or expansion into new technological areas, potentially challenging existing players in those markets, but the company's overall financial health remains a concern.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $205,798,707 as of September 30, 2025, and a net loss of $3,410,700 for the nine months ended September 30, 2025, indicating ongoing operational losses. Furthermore, the filing explicitly mentions risks related to 'our ability to maintain compliance with the applicable listing requirements of The Nasdaq Capital Market' and 'our ability to continue operating as a going concern,' highlighting significant financial instability and potential delisting concerns.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence. While the reduction in net loss and increased cash are positive, the substantial accumulated deficit and explicit 'going concern' risk mean GRDX is a highly speculative investment. Monitor future capital raises and the success of the Grid AI integration closely before considering any position.

Financial Highlights

total Assets

$135,370,340

total Debt

$45,808,262

net Income

-$3,410,700

eps

-$0.75

cash Position

$2,517,218

Key Numbers

• $3.41M — Net Loss (Reduced by 41.4% from $5.82M in 9M 2024 to $3.41M in 9M 2025)
• $2.52M — Cash and Cash Equivalents (Increased from $163K at Dec 31, 2024, to $2.52M at Sep 30, 2025)
• $205.8M — Accumulated Deficit (Increased from $202.4M at Dec 31, 2024, to $205.8M at Sep 30, 2025)
• $83.17M — Assets Held-for-Sale (Represents the value of the IMGX subsidiary intended for disposal)
• $24.99M — Additional Paid-in Capital from Grid AI (Resulted from the issuance of Series H preferred stock upon Grid AI acquisition)
• $3.03M — Proceeds from Equity Offering (Net proceeds from issuance of common stock, prefunded warrants, and warrants in 9M 2025)
• $32,080 — Research and Development Expenses (Decreased significantly from $882,522 in 9M 2024 to $32,080 in 9M 2025)
• $2.36M — General and Administrative Expenses (Decreased substantially from $13.54M in 9M 2024 to $2.36M in 9M 2025)
• 3,361,903 — Common Stock Shares Outstanding (As of November 18, 2025)
• $0.75 — Loss per Share (Q3 2025) (Improved from $1.76 in Q3 2024)

Key Players & Entities

• Entero Therapeutics, Inc. (company) — Registrant and parent company
• Grid AI Corp. (company) — Acquired subsidiary as of September 30, 2025
• IMGX (company) — Subsidiary classified as disposal group held-for-sale
• The Nasdaq Capital Market (regulator) — Exchange where common stock is registered
• $3,410,700 (dollar_amount) — Net loss for the nine months ended September 30, 2025
• $5,821,067 (dollar_amount) — Net loss for the nine months ended September 30, 2024
• $2,517,218 (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $163,476 (dollar_amount) — Cash and cash equivalents as of December 31, 2024
• $205,798,707 (dollar_amount) — Accumulated deficit as of September 30, 2025
• $83,170,009 (dollar_amount) — Assets of disposal group held-for-sale as of September 30, 2025

FAQ

Risk Factors

• Continued Operating Losses and Need for Capital [high — financial]: The company reported a net loss of $3,410,700 for the nine months ended September 30, 2025. Despite a significant reduction in expenses, the company continues to operate at a loss, necessitating the securement of additional capital to fund its ongoing operations and strategic initiatives.
• Nasdaq Listing Requirements [medium — regulatory]: The company faces risks related to maintaining its listing on the Nasdaq Stock Market. Failure to meet ongoing listing requirements could result in delisting, significantly impacting liquidity and investor confidence.
• Integration of Grid AI Corp. [medium — operational]: The acquisition of Grid AI Corp. on September 30, 2025, introduced significant intangible assets like developed technology ($18,387,000) and goodwill ($25,796,163). Successful integration and realization of the value of these acquired assets are critical for future performance.
• Divestiture of Assets [medium — financial]: The company has identified assets of a disposal group held-for-sale totaling $83,170,009. The successful completion of this divestiture is crucial for its financial strategy, but potential challenges in execution or valuation could arise.

Industry Context

Entero Therapeutics operates in the biotechnology sector, characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is competitive, with companies often seeking strategic acquisitions or divestitures to optimize their portfolios and secure funding. Recent trends include consolidation and a focus on innovative therapies, but also increased scrutiny on financial sustainability.

Regulatory Implications

The company must continue to meet Nasdaq's listing requirements, which typically include minimum bid price, market capitalization, and financial reporting standards. Failure to do so could lead to delisting. Additionally, ongoing compliance with SEC reporting and accounting standards is paramount.

What Investors Should Do

1. Monitor the progress and outcome of the asset divestiture (disposal group).
2. Assess the integration and performance of Grid AI Corp.
3. Evaluate the company's cash burn rate and future financing needs.
4. Track Nasdaq compliance efforts.

Key Dates

• 2025-09-30: Acquisition of Grid AI Corp. — Introduced significant developed technology and goodwill to the balance sheet, representing a major strategic move.
• 2025-09-30: End of Nine-Month Period — Reporting period for the condensed consolidated financial statements, showing a reduced net loss and increased cash.
• 2025-12-31: Prior Year End (December 31, 2024) — Baseline for comparison of cash position and accumulated deficit.

Glossary

Developed technology, net

The value of technology created or acquired by the company that is expected to provide future economic benefits, net of any accumulated amortization. (A significant intangible asset acquired through the Grid AI Corp. acquisition, impacting the company's asset base.)

Goodwill

An intangible asset that arises when one company acquires another for a price greater than the fair market value of its identifiable net assets. (A substantial amount of goodwill was recorded following the Grid AI Corp. acquisition, indicating a premium paid for the acquisition.)

Assets of disposal group held-for-sale

Assets and liabilities that a company intends to sell, classified separately on the balance sheet and reported at the lower of their carrying amount or fair value less costs to sell. (Represents a significant portion of the company's assets, indicating a planned divestiture of a business unit or subsidiary.)

Prefunded warrants

A type of warrant that is exercised immediately upon issuance, effectively acting as a prepaid option to purchase shares, often used in financing rounds to simplify the process. (Part of the equity offering that contributed to the increase in cash, indicating a specific financing instrument used.)

Accumulated deficit

The cumulative net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability, which increased from $202.4M to $205.8M during the nine-month period.)

Year-Over-Year Comparison

Compared to the prior-year period, Entero Therapeutics has significantly reduced its net loss by 41.4%, from $5.82M to $3.41M for the nine months ended September 30, 2025. This improvement is largely due to drastic cuts in General and Administrative expenses (down from $13.54M to $2.36M) and Research and Development expenses (down from $882K to $32K). The company's cash position has dramatically improved, rising from $163K at year-end 2024 to $2.52M, bolstered by equity financing. A major development is the acquisition of Grid AI Corp., adding substantial intangible assets and goodwill, alongside the planned divestiture of a large asset group.

Key Financial Figures

• $0.0001 — ch Registered Common stock, par value $0.0001 per share ENTO The Nasdaq Capital M

Filing Documents

• ento-20250930x10q.htm (10-Q) — 2169KB
• ento-20250930xex31d1.htm (EX-31.1) — 12KB
• ento-20250930xex31d2.htm (EX-31.2) — 12KB
• ento-20250930xex32d1.htm (EX-32.1) — 8KB
• 0001104659-25-114181.txt ( ) — 10671KB
• ento-20250930.xsd (EX-101.SCH) — 78KB
• ento-20250930_cal.xml (EX-101.CAL) — 62KB
• ento-20250930_def.xml (EX-101.DEF) — 436KB
• ento-20250930_lab.xml (EX-101.LAB) — 723KB
• ento-20250930_pre.xml (EX-101.PRE) — 608KB
• ento-20250930x10q_htm.xml (XML) — 1702KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Unaudited Condensed Consolidated Financial Statements 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 44 Item 4.

Controls and Procedures

Controls and Procedures 44

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 45 Item 1A.

Risk Factors

Risk Factors 45 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 45 Item 3. Defaults Upon Senior Securities 45 Item 4. Mine Safety Disclosures 45 Item 5. Other Information 45 Item 6. Exhibits 46

SIGNATURES

SIGNATURES Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (" Quarterly Report" ) contains forward-looking statements that involve substantial risks and uncertainties. All statements contained in this Quarterly Report other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "target", "potential", "will", "would", "could", "should", "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: our ability to maintain compliance with the applicable listing requirements of The Nasdaq Capital Market; our ability to satisfy our existing payment obligations and other payment obligations as they become due, including those related to the acquisition of First Wave Bio, Inc. and the Grid AI acquisition, as well as risks and uncertainties associated with integrating Grid AI's operations and meeting related financial commitments;

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to present fairly our financial position, results of operations, and cash flows for the interim periods presented. We have consolidated such financial statements in accordance with the rules and regulations of the Securities and Exchange Commission (" SEC "). Therefore, such financial statements do not include all disclosures required by accounting principles generally accepted in the United States of America. In preparing these unaudited condensed consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the date the unaudited condensed consolidated financial statements were issued by filing with the SEC. These financial statements should be read in conjunction with our audited financial statements for the year ended December 31, 2024, included in our Annual Report filed on Form 10 – K/A, filed with the SEC on April 9, 2025. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2025. -1- Table of Contents ENTERO THERAPEUTICS, INC. Consolidated Balance Sheets (unaudited) September 30, 2025 December 31, (unaudited and consolidated) 2024 ASSETS Current Assets: Cash and cash equivalents $ 2,517,218 $ 163,476 Accounts receivable 37,490 — Prepaid expenses 451,879 145,319 Assets of disposal group held-for-sale 83,170,009 83,170,009 Other current assets 1,521,939 — Total Current Assets 87,698,535 83,478,804 Other Assets: Restricted cash — 21,516 Property and equipment, net 27,520 — Developed technology, net 18,387,000 — Customer relationships 2,630,000 — Tr

View Full Filing

View this 10-Q filing on SEC EDGAR